When: Close above $327 on volume with positive MACD histogram

Then: Invalidates breakdown thesis; exit residual position or reassess

When: Daily close above 50 SMA at $338.84 with positive MACD histogram and follow-through

Then: Upgrade from Underweight to Hold/Overweight consideration

Trim 30-50% with relief bounce execution; oppose short exposure; rotate into cleaner quality setups

• Agrees SELL direction but opposes 60-75% trim plus tactical shorts as over-aggressive
• Recommends 30-50% trim with execution into relief bounce at 10 EMA
• Defends 22% EPS growth target as sell-side consensus aligned with CFO raised guidance
• Opposes short exposure due to theoretically unlimited upside risk on short positions
• Notes institutional anchor Berkshire Hathaway with no liquidity sell requirement
• Sentiment is bullish 7.1 out of 10, not fully embedded if stock capitulating 5% on heavy volume
• Q2 2026 delivered 10% revenue growth and 11% EPS growth YoY
• ROE above 34% with fresh product launch supports fundamental case
• Trader's plan with stop at 327 provides defined downside without additional directional risk
• Rotation into less-loved quality compounders with cleaner technical structures recommended

→ vs aggressive: Short exposure introduces asymmetric risk in the wrong direction - short positions have theoretically unlimited upside risk unlike defined-downside long positions

→ vs aggressive: 60-75% trim plus tactical shorts adds complexity without commensurate edge - multiple timing variables increase ways to be wrong

→ vs aggressive: 22% EPS growth target is not a heroic stretch but sell-side consensus consistent with CFO raised guidance and 8-10% long-term target band

→ vs aggressive: Confusing conviction with care - overly complicated tactical bet vs. surgical risk reduction

→ vs aggressive: Bullish sentiment at 7.1 not fully priced in since stock is capitulating 5% on heavy volume - fundamental and technical divergence exists

→ vs aggressive: Shorting AXP with Berkshire on cap table, ROE above 34%, raised guidance, and fresh product launch is reckless given positive catalyst risk

SELL - trim 45-50% of AXP position, scaling into relief bounce, no shorts, rotate proceeds into quality compounders over 2-4 weeks

• Technical breakdown confirmed: price below all major moving averages, close below lower Bollinger Band, MACD histogram expanding four times in two days, RSI at 31 (deep oversold but no bullish divergence)
• Trim recommendation is 45-50% (upper end of trader's 40-50% range) - 30% leaves 70% exposure to a bearish setup with 52-week low at $291 and psychological support at $300, while 60-75% gives up Q3 earnings optionality
• Execution: scale sales starting at $318, accelerating toward $321 (10 EMA rolling over at $321.59) rather than waiting for hard limit order at $321.59
• Stop at $327 as hard invalidation, but accept temporary breach of $322-$325 on relief bounce without abandoning position
• Reject short exposure entirely - asymmetric tail risk on high-quality name with Berkshire anchor, Q3 earnings, and potential Fed pivot
• Macro headwind confirmed: Fed hiked 25 basis points with more signaled, inflation probability above 4.5% rising, stagflationary setup compresses growth multiples
• Berkshire safe-haven partially valid: AXP has defensive characteristics (34% ROE, fee-based revenue mix) but not true defensive - beta proxy with discretionary exposure
• Bullish sentiment at 7.1/10 is mature but not euphoric - institutional support is data-backed (raised guidance, Berkshire endorsement, fresh product) rather than speculative
• Rotation thesis: proceeds into quality compounders with cleaner technicals (above key moving averages, RSI not overbought, price above VWAP) over 2-4 week window
• Three catalysts to monitor: (1) FOMC pause/pivot signals - asymmetric upside risk, (2) Q3 earnings in late October - net charge-off trends and forward NII guidance, (3) Business Banking adoption metrics - structural growth narrative

→ vs aggressive: His 'loaded spring' framing provides false certainty - RSI at 31 historically marks short-term bottoms, and mean reversion from oversold is reliable; his 22% EPS growth framing ignores that this is literally what the sell-side consensus, CFO, and 8-10% revenue target band all point toward, suggesting he knows better than the entire analyst community on a high-ROE (34%) name with $13B YoY balance sheet expansion

→ vs aggressive: His Berkshire safe-haven dismissal overcorrects - AXP has 34% ROE, raised guidance, and fresh product expansion, making it more defensive than most financials given fee-based revenue mix; in a Red October scenario it likely sells off but recovers first on way back up

→ vs aggressive: His 60-75% trim plus shorts requires being right about both magnitude and timing to justify giving up Q3 earnings optionality - overcorrecting to his worst rhetorical instincts

→ vs conservative: His 30-50% trim potentially undershoots given stacked bearish signals - 30% trim leaves 70% exposure to a setup where every indicator is bearish with next support at $300 and 52-week low at $291

→ vs conservative: His assumption that fundamentals provide a floor under technical damage is empirically false for single-name positions over short timeframes - stock fell 5% in two days on heavy volume while CFO was still being bullish; fundamentals don't show up in the tape until earnings (6 weeks away)

→ vs conservative: He underweights multiple compression risk - if growth disappoints by even a couple points relative to consensus, 15.5x forward P/E can compress to 12-13x, a 20% move on the multiple alone before any earnings miss

→ vs conservative: His bullish sentiment argument is circular logic - that sentiment isn't fully embedded because the stock is falling - when price action and sentiment can diverge for extended periods; analyst targets are lagging indicators by design and will revise lower over 30-60 days